NASHVILLE, Tenn., Jan. 15, 2025 — 3LS Ventures Inc., a leading early-stage investor specializing in behavioral health solutions, is proud to announce its strategic investment in Xuron, an innovative healthcare technology company that provides a virtual, intelligent provider training aimed at simulating the patient experience. This partnership demonstrates 3LS Ventures’ unwavering commitment to accelerating advancements in healthcare through technology and innovation.

“At 3LS Ventures, we are committed to supporting early-stage companies driving transformative innovations that redefine care and improve lives,” said Eric Strickland, CEO of 3LS Inc. “Our investment in Xuron will accelerate their use of AI technology to enhance training for a broader range of clinical and human service professionals, ultimately improving patient outcomes. We are thrilled to partner with Xuron’s exceptional team as they work to make meaningful advancements in quality patient care.”

Based in Nashville, 3LS Ventures focuses on identifying and supporting mission-driven startups that address critical needs in behavioral health. This latest investment in Xuron builds on the firm’s portfolio of solutions designed to create measurable, positive impacts for individuals and communities. Xuron, known for its AI-powered platform, has already demonstrated success in deploying its first-generation tools with early adopters spanning top 20 pharmaceutical companies, multi-state health systems, esteemed medical schools, and prominent continuing medical education (CME) organizations. With 3LS Ventures’ backing, Xuron is poised to accelerate the development of its next-generation suite, which integrates virtual humans and data-driven insights to improve behavioral outcomes.

“Xuron represents the type of company we look to support—innovative, impactful, and aligned with our mission to advance healthcare,” said Gina Drobnick, CEO of 3LS Ventures. “This investment not only enhances our portfolio but also reinforces our commitment to partnering with companies that deliver real solutions for improving lives.”

The partnership highlights 3LS Ventures’ focus on fostering innovation that matters. By supporting Xuron, the firm aims to scale transformative technologies that improve the training and education of healthcare professionals, ensuring better outcomes for patients nationwide.

“As a native Nashville founder, it’s great to have a local investment team on our side,” said Ian Nott, CEO of Xuron. “Their focus in the behavioral health space provides crucial support as we grow and expand. Our vision is to improve the quality of care for Tennesseans and all Americans. We achieve this by focusing on the nuances of human social interactions that are critical to both individual lives and our collective social fabric.”

3LS Ventures continues to lead the charge in behavioral health innovation, investing in groundbreaking solutions that redefine care and improve access. This strategic partnership with Xuron is a testament to the firm’s dedication to creating a lasting impact in the behavioral health landscape.

About 3LS Ventures Inc.

3LS Ventures Inc. is a wholly owned subsidiary of 3LS Inc., a Nashville-based employee-owned company that provides administrative and advisory services to human service organizations. 3LS Ventures launched in November 2023 to invest in early-stage companies’ solutions that are accelerating positive behavioral health and well-being outcomes.

About Xuron

Xuron is a groundbreaking healthcare technology company leveraging artificial intelligence to revolutionize healthcare education. Its platform combines virtual humans with advanced data analytics to deliver and measure positive behavioral outcomes, empowering healthcare professionals with cutting-edge training tools. With a focus on real-world impact and measurable results, Xuron is redefining care to improve lives nationwide.

For more information, contact:
[email protected]

SOURCE 3LS Ventures Inc

Pioneering Firm Continues to Lead in Secondary Private Equity, with Succession Leadership in Place and Plans to Grow the Firm and Team Going Forward

NEW YORK, Jan. 15, 2025 — VCFA Group (VCFA), a pioneer in the secondary private equity industry, today announced the successful close of its latest fund, VCFA Venture Partners VII, L.P. (VCFA VP VII), with capital commitments totaling $122.5 million. This fund continues VCFA’s leadership in the secondary market, focusing on smaller, more complex purchases of later-stage venture capital and growth equity assets.

The close of VCFA VP VII marks a significant milestone in the firm’s four decades in operation. Established in 1982 by Dayton Carr, VCFA is known for being the first firm focused on secondary private equity. Dayton passed away in 2020 during the fundraise for the predecessor fund, VCFA Venture Partners VI, L.P. (VCFA VP VI). The firm commenced a succession plan with David Tom and Andrew Reilly assuming leadership and ownership of VCFA and culminating with a final closing of VCFA VP VI in March 2021 with $107.2 million in capital commitments. In total, VCFA Group has now raised $229.7 million in its flagship secondary fund strategy under David and Drew. This leadership transition marks the continuation of VCFA’s legacy of pioneering the secondary private equity space.

David Tom, Managing Member of VCFA, commented, “We are thankful to the investors who have supported us through multiple funds and new investors who have put their trust in us. The demand for liquidity solutions for mature venture and growth-stage fund interests at the smaller end of the market is greater than I have ever seen. We are seeing more sellers looking for tailored, flexible capital solutions below $50 million in size. With VCFA VP VII closed, we are well-positioned to build on our leadership in the secondary market and continue growing VCFA into a next-generation firm.”

Andrew Reilly, Managing Member of VCFA, added, “We are proud to carry forward the vision Dayton Carr established more than four decades ago. Our team’s deep experience, combined with our track record of success in navigating complex transactions, uniquely positions us to execute on this strategy. As we look ahead, we are excited to expand on our core venture growth secondary strategy while also exploring complementary secondary strategies that will continue to diversify our offerings and meet the evolving needs of our investors.”

In connection with the new fundraise, VCFA is also promoting two members of the investment team. Andy Coke, who joined VCFA in 2019, was promoted from Senior Associate to Vice President. Andy graduated from Brown University and held equity research positions prior to joining VCFA. Colin Moffet, who joined VCFA from Princeton in 2021, was promoted from Analyst to Associate.

VCFA VP VII is targeting transactions involving seasoned venture capital and growth equity assets, where the need for liquidity or portfolio realignment creates opportunities for secondary investors. These transactions are often more nuanced, requiring a deep understanding of both the operational and financial needs of portfolio companies and the intricate capital structures of these assets.

For more information on VCFA Venture Partners VII, L.P., or if you are considering selling private equity, please contact:
Susan Harris
VCFA Group
[email protected]
212-838-5577

About VCFA Group (VCFA)
Founded in 1982, VCFA Group (VCFA) became the first firm primarily focused on the acquisition of interests in private equity funds on a secondary basis and is a pioneer in the concept of secondary purchases of limited partnership interests and GP-led transactions. To date, VCFA Group has raised eleven funds and returned over $1 billion to its limited partners. Those that have sold private equity interests to VCFA include state pension funds, the federal government, Fortune 100 companies, some of the largest banks, financial institutions and insurance companies, foundations, and wealthy individuals. VCFA prides itself on discretion, good relations in the private equity community, and streamlined transfers. Additional information regarding VCFA is available at www.vcfa.com.

SOURCE VCFA Group

Origis Energy welcomes Brookfield Asset Management into its investor group, alongside majority owner, Antin Infrastructure Partners, to support U.S. growth ambitions.

MIAMI and NEW YORK, Jan. 15, 2025 — Origis Energy, one of America’s leading renewable energy platforms, today announced a new strategic investment from Brookfield Asset Management Ltd. alongside new commitments from existing sponsor, Antin Infrastructure Partners, which could exceed $1 billion in the aggregate.

Brookfield is investing through its Infrastructure Structured Solutions strategy, alongside affiliated entities. This additional capital and support from an established player will accelerate Origis Energy’s progress as an independent power producer and advance its portfolio of solar and battery storage assets at a time of unprecedented demand for clean electricity from its customers.

An Antin portfolio company since 2021, Origis Energy develops, builds and operates large-scale renewable energy projects in the United States, a market that benefits from significant tailwinds. Today, the company operates an approximately one gigawatt (1 GW) solar and storage project portfolio across four states with an additional 3 GW of in-construction or construction-ready projects and a further 25 GW total development pipeline. S&P recently ranked Origis fifth on its 2024 list of the largest solar developers in the U.S. through 2028.ⁱ

Vikas Anand, Chief Executive Officer of Origis Energy, said: “We are excited to welcome Brookfield as a new significant investor and are grateful for Antin’s continued leadership. With two of the world’s most well-respected renewable power infrastructure investors as our partners, we will accelerate our mission and strategy to provide cost-effective, carbon-free electricity to customers across the United States.”

Hamish Kidd, Managing Director in Brookfield’s Infrastructure business, commented: “We are thrilled with this new partnership with Origis Energy. As one of the world’s largest investors in renewable energy, we look forward to utilizing our relationships and capital to scale-up the platform and meet the U.S.’s growing demand for clean power.”

Guillaume Friedel, Partner of Antin, added: “Our continued support for the Origis Energy platform is a testament to the strength of its management team, strong customer relationships and high-quality project portfolio. We are excited to embark on the next chapter of Origis’ growth and evolution and we are pleased to welcome Brookfield into the investor group.”

Origis Energy was advised by PJT Partners, J.P. Morgan, and Santander with Latham & Watkins serving as legal advisors. Vinson & Elkins served as Brookfield’s legal advisor.

About Origis Energy
Origis Energy is accelerating the transition to a carbon-free future. As one of America’s leading renewable energy and decarbonization solution platforms, the company continues to expand and reimagine its contribution to the world’s net-zero goals. Origis Energy puts customers first to deploy a wide range of sustainable solutions for grid power generation and performance, clean hydrogen and long-term operation of solar, energy storage and clean hydrogen plants across the U.S. Founded in 2008, Origis Energy is headquartered in Miami, FL. Learn more at www.origisenergy.com.    

About Antin Infrastructure Partners
Antin Infrastructure Partners is a leading private equity firm focused on infrastructure. With over €32 billion in assets under management across its Flagship, Mid Cap and NextGen investment strategies, Antin targets investments in the energy and environment, digital, transport and social infrastructure sectors. With offices in Paris, London, New York, Singapore, Seoul and Luxembourg, Antin employs over 240 professionals dedicated to growing, improving and transforming infrastructure businesses while delivering long-term value to portfolio companies and investors. Majority owned by its partners, Antin is listed on Euronext Paris (Ticker: ANTIN – ISIN: FR0014005AL0).

About Brookfield Asset Management
BAM is a leading global alternative asset manager with over $1 trillion of assets under management across renewable power and transition, infrastructure, private equity, real estate, and credit. BAM invests client capital for the long-term with a focus on real assets and essential service businesses that form the backbone of the global economy. BAM offers a range of alternative investment products to investors around the world — including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors. BAM draws on Brookfield’s heritage as an owner and operator to invest for value and generate strong returns for its clients, across economic cycles.

SOURCE Origis Energy

Eisen Brings Proven Track Record of Building Leading Fintech Platforms to Power Reshop Into Its Next Phase of Growth

NEW YORK, Jan. 15, 2025 — Today, Reshop, the platform redefining refunds for consumers and merchants, announced the appointment of Anthony Eisen as Chief Executive Officer. Anthony has been a part of Reshop since inception, serving as Chairman of the Board and a founding investor at Reshop. In addition, Reshop announced a $17 million fundraise, with leading investments from Matrix Partners, Sound Ventures (venture-capital firm co-founded by Ashton Kutcher and Guy Oseary), Woodson Capital, and Touch Ventures.

Anthony most recently served as Co-Founder and Co-CEO of Afterpay, which he launched alongside Nick Molnar in 2014 and listed on the ASX in May 2016. He has over 25 years of experience in investing, building companies, maintaining public company directorships and providing corporate advice. Prior to co-founding Afterpay, Anthony was the Chief Investment Officer at Guinness Peat Group (GPG). He was actively involved in a number of financial services, software and technology companies in which GPG was a major shareholder.

“With Afterpay, our mission has always been to power an economy in which everyone wins, and that holds true with Reshop as well,” said Anthony Eisen. “The refunds space is ripe for disruption and in need of a solution that benefits both retailers and consumers, which is what we’re providing with Reshop. I’m proud of the progress the team has already made since launching earlier this year and am excited to help shape the next chapter in the Reshop journey.”

During his time at Afterpay, Anthony helped lead a generational shift toward responsible spending behaviors and away from high-interest credit cards, turning something that was unheard of into a norm in the shopping experience. Leveraging his expertise in the space, Anthony will power Reshop into its next phase of growth, paving the way for this new category that the team has identified in the post-purchase funnel. As Reshop continues to expand its network of partner retailers (which currently includes Alo Yoga, Steve Madden, Dolce Vita, Alala, and P.J. Salvage), the $17 million fundraise will be used to accelerate go to market and scale.

“In order to be successful as a retailer in today’s landscape, it is critical to provide convenient options that offer a quick and seamless shopping experience from start to finish,” said Dana Stalder, General Partner at Matrix Partners. “Reshop has uncovered an entirely new space in the post-purchase experience and the platform’s growth to-date speaks to the opportunity at hand. We believe Reshop will become integral to the shopping journey for any brand.”

Early adoption of the platform has shown that Reshop is already driving significant impact for retailers, with 1 in 2 customers making a repeat purchase from the original merchant and with the majority of repeat purchases happening in less than 24 hours and in some cases in as little as one minute. Moving forward, Anthony will continue to maximize Reshop’s impact on the shopping experience.

About Reshop
Launched in 2024, Reshop is focused on making refunds faster and more rewarding for both shoppers and merchants. By providing shoppers with immediate access to their money, Reshop helps increase satisfaction and drive more sales for retailers. For more information, visit Reshop.com.

Press Contact: 
[email protected]

SOURCE Reshop

BOSTON, Jan. 15, 2025 — Granata Bio Corporation (“Granata Bio”), a biopharma company focused on invigorating the $3.6B global infertility medication market, today announced its $15M Series A+ funding round. The round was exclusively supported by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic investors. Granata has raised over $30 million to date.

This funding round will primarily support Granata Bio’s efforts to progress its existing pipeline and explore new innovative assets in reproductive health. With this investment, Granata Bio is focused on strengthening its leadership within the reproductive health space and continuing to identify and grow innovative solutions for patients.

Evan Sussman, CEO of Granata Bio, expressed gratitude for ongoing support, stating “we are grateful for the continued confidence and commitment shown by our existing investors, especially our strategic partners who are leaders in women’s health, Gedeon Richter and CooperSurgical. Granata Bio is committed to improving access for fertility patients by identifying and developing new therapeutic solutions. With this new funding, we are well-positioned to accelerate the development of our current and future pipeline.”

Granata Bio was represented by Mintz in the funding round.

About Granata Bio
Granata Bio is a US-based biopharma company focused on women’s health and infertility. Founded in 2018, Granata’s pipeline includes collaborations spanning multiple IVF product classes. To learn more about Granata Bio, visit www.granata.bio.
For all inquiries contact [email protected].

About Gedeon Richter
Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest, Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 4.3bn (USD 4.7bn) by the end of 2023, Richter’s consolidated sales were approximately EUR 2.1bn (USD 2.3bn) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s Healthcare field worldwide. Richter is also active in developing, manufacturing and commercializing biosimilars for the treatment of osteoporosis, rheumatoid arthritis and other auto-immune diseases.

CooperSurgical
CooperSurgical® is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women’s healthcare providers, including testing and treatment options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies. CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women’s health care clinicians. More information can be found at www.coopersurgical.com.

SOURCE Granata Bio

HUNTINGTON, N.Y., Jan. 15, 2025 — Sen-Jam Pharmaceutical is excited to announce the preliminary results from its recently completed Phase 2 clinical trial evaluating the safety and efficacy of SJP-002C, a novel therapeutic for the treatment of Upper Respiratory Infections such as COVID-19.

Key Highlights of the Trial Results:

• Safety: SJP-002C demonstrated an exceptional safety profile, with no adverse events reported during the trial period, highlighting its potential as a safe therapeutic option for COVID-19.
• Efficacy: The therapeutic significantly improved symptom reduction during the critical early stages of treatment, particularly on days 1 and 2.

What These Results Mean

These findings reinforce SJP-002C’s promise as a groundbreaking therapeutic for COVID-19 and Upper Respiratory Infections, demonstrating both safety and early efficacy. While further studies are needed to validate its statistical and clinical significance, the trial results encourage continued development and exploration of the therapeutic’s broader potential.

“The strong safety profile and early symptom improvements are promising indicators of SJP-002C’s potential to make a meaningful impact in COVID-19 care,” said Jackie Iversen RPh MS, Chief Clinical Officer and Co-Founder, Sen-Jam Pharmaceutical. “We are energized by these results and remain committed to refining the efficacy of this therapeutic to serve a broader population.”

Next Steps

Sen-Jam is actively reviewing additional clinical data to deepen its understanding of SJP-002C’s performance and efficacy. The company is also exploring opportunities for follow-up studies that could expand the scope of the therapeutic’s application to broader patient populations and conditions.

Join Us at the JPMorgan Healthcare Conference in San Francisco

Sen-Jam Pharmaceutical’s leadership team is attending the prestigious JPMorgan Healthcare Conference in San Francisco this week. The company invites partners, investors, and stakeholders to connect, learn more about its innovative pipeline, and explore partnership opportunities. Together, we can shape the future of healthcare. To learn more about Sen-Jam Pharmaceutical’s vision and mission, visit wefunder.com/senjam.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care
Sen-Jam Pharmaceutical (“Sen-Jam”) is pioneering a revolutionary approach to addressing chronic inflammation and metabolic disorders with its proprietary “Pleiotropic Anti-Inflammatory Remedies” (PAIR) technology. By working in harmony with the body’s innate immune system, Sen-Jam’s precision remedies target inflammation at its source, mitigating systemic risks associated with chronic conditions without suppressing immune responses.

As a leader in innovative healthcare, Sen-Jam is delivering treatments that enhance metabolic health, promote vitality, and extend health spans. The company is redefining how the world heals by focusing on solutions that balance cutting-edge science with the body’s natural resilience.

CONTACT INFORMATION:

Sen-Jam Pharmaceutical
Christine Leonard
[email protected]
781-913-1902

SOURCE Sen-Jam Pharmaceutical

Fourteen organizations in seven countries will receive support for innovative projects focused on advancing children’s health, ranging from improved treatments to sweeping public health initiatives

NEW YORK, Jan. 15, 2025 — The Deerfield Foundation, a philanthropic affiliate of New York City-based healthcare investment firm Deerfield Management, today announced the awarding of $1.5 million in support for 14 not-for-profit organizations in seven countries to improve the health of children and their families in 2025.

“At the Deerfield Foundation, we’ve been dedicated for nearly 20 years to funding initiatives that drive positive change in health, innovation and equity – especially for children and the communities where they live,” said Mark Veich, Board Member of the Deerfield Foundation. “Through our targeted grants, we support organizations working to create breakthrough therapies, expand access to care, and strengthen public health efforts, all with the goal of improving lives at the individual and community level.”

Since its establishment as a private, not-for-profit entity in 2005, the Deerfield Foundation has awarded more than $50 million to over 125 organizations. The Foundation administers grants in support of a key pillar of Deerfield Management’s mission: to advance healthcare through investment, information, and philanthropy. Its funding is supported not only by Deerfield profits but also by the continued generosity of Deerfield employees, who contribute to the Foundation’s effort to create lasting improvements in health and well-being across communities.

Organizations selected by the Deerfield Foundation will receive one-year grants to support initiatives focused on pediatric and adolescent health beginning in January 2025. This year, a volunteer program committee of 30 Deerfield employees reviewed funding proposals based on their potential to achieve direct, measurable impact, as well as opportunities for Deerfield employees to engage in meaningful collaboration with grantees. In alignment with the Foundation’s commitment to fostering partnerships, all grantees are invited to submit proposals by Deerfield employees, as the Foundation does not accept unsolicited funding requests.

Of the 2025 grantees, eight are based in the United States and an additional six are global organizations. The 2025 grantees are:

Augmenting the impact of its annual grants, the Deerfield Foundation and Deerfield Management established the Advancium Health Network in 2022. This public charity is committed to removing barriers to healthcare advancement and aims to be a leading force in health technology and innovation, focusing on areas of urgent need. Additionally, in June 2023, the Deerfield Foundation introduced a research award created in memory of longtime Deerfield Partner, Peter Steelman. The American Society of Hematology Peter Steelman Scholar Award supports research into acute myeloid leukemia (AML), a form of cancer affecting the blood and bone marrow.

About the Deerfield Foundation
An affiliate of Deerfield Management, the Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to strive to improve health, accelerate innovation, and promote human equity. Since its inception in 2005, the Foundation has formed numerous partnerships and invested in the advancement of children’s health from clinics in the South Bronx to Nepal. Funds are provided through employee contributions and directly from Deerfield’s profits.

Deerfield contact:

Julianna Santamaria

[email protected]

Phone: (212) 583 – 8324

SOURCE Deerfield Management Company, L.P.

SAN JOSE, Calif., Jan. 15, 2025 — Visby Medical^™, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to accelerate its fight against antibiotic resistance. This funding builds on a $1.2 million grant awarded in December 2023 and propels Visby’s development of groundbreaking diagnostic tools that pinpoint resistance-conferring mutations in infections, starting with ciprofloxacin susceptibility.

The additional funding will advance Visby’s pioneering work funded by CARB-X, which has demonstrated its preliminary ability to detect Neisseria gonorrhoeae (NG) from urine and vaginal swabs and distinguish ciprofloxacin-susceptible strains. Next, Visby will continue development toward integrating these capabilities into its Visby Medical Sexual Health Test, which detects chlamydia, gonorrhea, and trichomoniasis. The company is also developing a digital companion app and AI-driven tools to make result interpretation seamless, while working on cost-cutting innovations for its platform.

Ciprofloxacin is a former frontline antibiotic that has been sidelined due to widespread resistance. With Visby’s rapid test, doctors could determine if this convenient, inexpensive oral antibiotic is effective and reserve ceftriaxone—currently the only antibiotic that remains effective against resistant gonorrhea—for truly resistant cases.

“Antibiotic resistance is a critical concern across all of healthcare, and especially in sexually transmitted infections for which numbers continue to rise,” explained Gary Schoolnik, MD, Chief Medical Officer of Visby Medical. “Particularly for N. gonorrhoeae, which is a poster child for acquiring resistance, unlocking the treatment potential of ciprofloxacin could mean the difference between extending the lifetime of ceftriaxone either for decades, or only a handful of years.”

About Visby Medical
Founded in 2012, Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company developed a proprietary technology platform that is the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Their commercialized point-of-care tests for sexually transmitted infections (STIs) and respiratory infections (COVID-19 and the flu) deliver true PCR results in under 30 minutes. For more information, visit www.visby.com. Follow Visby Medical on LinkedIn.

CARB-X funding for this research is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number 75A50122C00028, and by awards from Wellcome (WT224842), Germany’s Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views CARB-X or its funders.

Media Contact: [email protected]

SOURCE Visby Medical

AI for Architectural Planning that allows users to effortlessly generate layout plans and visualizations to further accelerate global adoption; users generate over 400 million square feet in record time

TEL AVIV, Israel, Jan. 15, 2025 — qbiq, the largest and one of the first AI companies focused on automating architectural planning, today announced the closing of a $16 million Series A round led by global software investor Insight Partners. The round included participation from JLL Spark, 10D, Ocean Azul, Random Forest and M-Fund.

qbiq’s software enables non-architects and architect users alike to immediately plan, visualize and optimize any given space. With a simple input of requirements – from seat count to finish materials – qbiq’s AI generates a complete design package including optimized floor plans, 3D visualizations, architectural programs, quantity estimates, Revit/CAD models and more. qbiq transforms complex design processes into easy-to-use solutions that can dramatically accelerate decision-making and transactions for brokers, landlords, tenants, architects, general contractors, and co-working chains.

The investment will drive qbiq’s mission to standardize automated architectural capabilities in commercial real estate, making architectural planning faster, accessible, and more efficient for non-designers and designers alike.

A New Era of Automated Architectural Capabilities

Since launch, qbiq’s customers have created over 400 million square feet of architectural layouts and visualizations in hours, replacing weeks or even months of manual work to accelerate decision-making and reduce deal cycles. The customer base has grown more than tenfold and qbiq continues to see increasing demand.

“When we officially launched in 2023, I discussed reaching 100 million square feet delivered to clients as a KPI. This was thought by many to be unrealistic. By 2024 we had already quadrupled that goal and are now speeding towards the 1 billion square foot mark,” says Leeor Solnik, qbiq’s CEO & Co-Founder. “Joining forces with Insight Partners is a big milestone for qbiq, enabling the acceleration of our global expansion and paving our way towards a real industry transformation.”

Liad Agmon, Managing Director at Insight Partners, led the investment in qbiq and will join the company’s board of directors.

“When I was CEO, we would have at least one major office move per year across our global offices. Understanding whether a vacant space would be optimal for our needs was a tedious and lengthy process that would often take weeks and involve back and forth between our team, landlords, and our architects. I was impressed by how elegantly qbiq solves this problem, saving valuable time and money to all parties involved.” said Agmon. “With qbiq, we’re witnessing a game-changing shift—helping define a new era of automated architectural planning.”

Ending the decades-long dependency on manual architectural workflows

qbiq tackles one of real estate’s biggest pain points: the inefficiency of traditional architectural planning, which leads to delays and prolonged deal cycles.

For decades, creating layouts involved slow, manual work using tools like AutoCAD, with architects solving complex design problems line by line. Even after completing a layout, interpreting it can be challenging—especially for those without a design background. Creating clarity through visuals, such as rendered tours and images, is a costly, months-long process, making it impractical for most deals and projects.

qbiq has created one of the first Architectural AI platforms that allows brokers, landlords, architects, general contractors, and tenants to easily envision the full potential of any space in minutes, while considering basic or complex requirements. Customers such as Brookfield Properties, JLL, Skanska and IWG are able to easily create a wide range of architectural outputs for any space in minutes. These outputs include architectural programs, programmatic or conceptual layouts, high-resolution rendered tours and images, quantity takeoffs CAD/Revit models and more.

About qbiq

qbiq leverages generative AI to automate and democratize architectural planning at any scale. With qbiq, tenants make highly informed decisions, brokers close deals and projects faster, landlords increase ROI from reduced vacancies due to shorter deal cycles and architects can boost their planning capacity. Founded in 2019 by Leeor Solnik, Elad Kaminer, Noam Diamantstein and Roey Granot. qbiq is headquartered in Tel Aviv, with offices in New York and Miami. To date, qbiq has delivered over 400 million square feet of plans, transforming real estate transactions for hundreds of clients globally.

For more information, visit qbiq.ai.

About Insight Partners

Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2024, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

SOURCE qbiq